微小RNA-223通过阻断缺氧驱动的血管生成和免疫抑制来减弱肝癌发生
本研究在二乙基亚硝胺(DEN)及慢性四氯化碳(CCl4)处理的原位肝癌细胞植入两种炎症相关肝癌小鼠模型中,发现miR-223基因敲除显著加剧肿瘤发生,其通过抑制缺氧诱导因子1α驱动的CD39/CD73-腺苷通路间接下调PD-1/PD-L1,腺病毒递送miR-223可抑制血管生成和缺氧介导的PD-1/PD-L1激活,从而阻碍肝癌进展。
要点
- miR-223基因敲除显著加剧炎症相关肝癌的肿瘤发生。
- miR-223通过抑制缺氧诱导因子1α驱动的CD39/CD73-腺苷通路间接下调PD-1/PD-L1。
- 腺病毒递送miR-223可抑制血管生成和缺氧介导的PD-1/PD-L1激活,阻碍肝癌进展。
核心结论
- miR-223在调节缺氧诱导的肿瘤免疫抑制和血管生成中起关键作用,可能作为肝癌的新治疗靶点。
研究设计与样本
- 野生型和miR-223敲除小鼠接受两种炎症相关肝癌模型:二乙基亚硝胺(DEN)注射或慢性四氯化碳(CCl4)处理小鼠的原位肝癌细胞植入。
主要发现
- 与野生型小鼠相比,miR-223敲除小鼠在DEN+CCl4给药后浸润的PD-1+ T细胞和PD-L1+巨噬细胞更多。
- RNA测序数据的生物信息学分析显示miR-223水平与肿瘤缺氧强相关。
- 体内和体外机制研究表明miR-223不直接靶向免疫细胞中的PD-1和PD-L1,而是通过抑制肝癌中缺氧诱导因子1α驱动的CD39/CD73-腺苷通路调节肿瘤微环境来间接下调它们。
- 通过腺病毒递送miR-223在两种肝癌模型中均抑制血管生成和缺氧介导的PD-1/PD-L1激活,从而阻碍肝癌进展。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The current treatment for hepatocellular carcinoma (HCC) to block angiogenesis and immunosuppression provides some benefits only for a subset of patients with HCC, thus optimised therapeutic regimens are unmet needs, which require a thorough understanding of the underlying mechanisms by which tumour cells orchestrate an inflamed tumour microenvironment with significant myeloid cell infiltration. MicroRNA-223 (miR-223) is highly expressed in myeloid cells but its role in regulating tumour microenvironment remains unknown. DESIGN: Wild-type and miR-223 knockout mice were subjected to two mouse models of inflammation-associated HCC induced by injection of diethylnitrosamine (DEN) or orthotopic HCC cell implantation in chronic carbon tetrachloride (CCl4)-treated mice. RESULTS: Genetic deletion of miR-223 markedly exacerbated tumourigenesis in inflammation-associated HCC. Compared with wild-type mice, miR-223 knockout mice had more infiltrated programmed cell death 1 (PD-1+) T cells and programmed cell death ligand 1 (PD-L1+) macrophages after DEN+CCl4 administration. Bioinformatic analyses of RNA sequencing data revealed a strong correlation between miR-223 levels and tumour hypoxia, a condition that is well-documented to regulate PD-1/PD-L1. In vivo and in vitro mechanistic studies demonstrated that miR-223 did not directly target PD-1 and PD-L1 in immune cells rather than indirectly downregulated them by modulating tumour microenvironment via the suppression of hypoxia-inducible factor 1α-driven CD39/CD73-adenosine pathway in HCC. Moreover, gene delivery of miR-223 via adenovirus inhibited angiogenesis and hypoxia-mediated PD-1/PD-L1 activation in both HCC models, thereby hindering HCC progression. CONCLUSION: The miR-223 plays a critical role in modulating hypoxia-induced tumour immunosuppression and angiogenesis, which may serve as a novel therapeutic target for HCC.
引用
- Fu Y, Mackowiak B, Feng D, et al. MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression. Gut. 2023. PMID: 36593103. doi:10.1136/gutjnl-2022-327924
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。